Trials / Completed
CompletedNCT00607750
Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF
A Phase 2 Randomized, Double-Masked, Study to Evaluate the Safety and Preliminary Efficacy of ATG003 in Patients With Neovascular Age-Related Macular Degeneration (NV-AMD) Receiving Frequent Maintenance Intravitreal Anti-VEGF Antibody Therapy (Ranibizumab or Bevacizumab)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- CoMentis · Industry
- Sex
- All
- Age
- 56 Years
- Healthy volunteers
- Not accepted
Summary
This study is a double-masked, randomized, placebo-controlled study of the safety and preliminary efficacy of ATG003 (topical mecamylamine) in patients receiving maintenance injections of either ranibizumab or bevacizumab. Study Hypothesis: Mecamylamine could be effective in the treatment of neovascular AMD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATG003 (mecamylamine) | 1% Ophthalmic solution, eyedrop BID, 48 weeks |
| DRUG | Placebo | Placebo eyedrops, BID, 48 weeks |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2010-04-01
- Completion
- 2010-05-01
- First posted
- 2008-02-06
- Last updated
- 2010-10-28
Source: ClinicalTrials.gov record NCT00607750. Inclusion in this directory is not an endorsement.